Literature DB >> 27217331

Effects of G6PD activity inhibition on the viability, ROS generation and mechanical properties of cervical cancer cells.

Zishui Fang1, Chengrui Jiang1, Yi Feng1, Rixin Chen1, Xiaoying Lin1, Zhiqiang Zhang1, Luhao Han1, Xiaodan Chen1, Hongyi Li1, Yibin Guo1, Weiying Jiang2.   

Abstract

Glucose-6-phosphate dehydrogenase (G6PD) deficiency has been revealed to be involved in the efficacy to anti-cancer therapy but the mechanism remains unclear. We aimed to investigate the anti-cancer mechanism of G6PD deficiency. In our study, dehydroepiandrosterone (DHEA) and shRNA technology were used for inhibiting the activity of G6PD of cervical cancer cells. Peak Force QNM Atomic Force Microscopy was used to assess the changes of topography and biomechanical properties of cells and detect the effects on living cells in a natural aqueous environment. Flow cytometry was used to detect the apoptosis and reactive oxygen species (ROS) generation. Scanning electron microscopy was used to observe cell morphology. Moreover, a laser scanning confocal microscope was used to observe the alterations in cytoskeleton to explore the involved mechanism. When G6PD was inhibited by DHEA or RNA interference, the abnormal Young's modulus and increased roughness of cell membrane were observed in HeLa cells, as well as the idioblasts. Simultaneously, G6PD deficiency resulted in decreased HeLa cells migration and proliferation ability but increased ROS generation inducing apoptosis. What's more, the inhibition of G6PD activity caused the disorganization of microfilaments and microtubules of cytoskeletons and cell shrinkage. Our results indicated the anti-cervix cancer mechanism of G6PD deficiency may be involved with the decreased cancer cells migration and proliferation ability as a result of abnormal reorganization of cell cytoskeleton and abnormal biomechanical properties caused by the increased ROS. Suppression of G6PD may be a promising strategy in developing novel therapeutic methods for cervical cancer.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Anti-tumor; Cervical cancer cell; Cytoskeleton; G6PD deficiency; Mechanical properties

Mesh:

Substances:

Year:  2016        PMID: 27217331     DOI: 10.1016/j.bbamcr.2016.05.016

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  17 in total

1.  Nuclear factor E2-related factor-2 has a differential impact on MCT1 and MCT4 lactate carrier expression in colonic epithelial cells: a condition favoring metabolic symbiosis between colorectal cancer and stromal cells.

Authors:  K Diehl; L-A Dinges; O Helm; N Ammar; D Plundrich; A Arlt; C Röcken; S Sebens; H Schäfer
Journal:  Oncogene       Date:  2017-08-28       Impact factor: 9.867

2.  G6PD promotes cell proliferation and dexamethasone resistance in multiple myeloma via increasing anti-oxidant production and activating Wnt/β-catenin pathway.

Authors:  Rui Li; Mengying Ke; Mingming Qi; Zhenru Han; Yuhao Cao; Zhendong Deng; Jinjun Qian; Ye Yang; Chunyan Gu
Journal:  Exp Hematol Oncol       Date:  2022-10-21

Review 3.  Dehydroepiandrosterone on metabolism and the cardiovascular system in the postmenopausal period.

Authors:  Caio Jordão Teixeira; Katherine Veras; Carla Roberta de Oliveira Carvalho
Journal:  J Mol Med (Berl)       Date:  2019-11-12       Impact factor: 4.599

4.  Dehydroepiandrosterone inhibits ICa,L and its window current in voltage-dependent and -independent mechanisms in arterial smooth muscle cells.

Authors:  Rikuo Ochi; Sukrutha Chettimada; Igor Kizub; Sachin A Gupte
Journal:  Am J Physiol Heart Circ Physiol       Date:  2018-10-31       Impact factor: 4.733

Review 5.  Mechanisms of Metabolic Reprogramming in Cancer Cells Supporting Enhanced Growth and Proliferation.

Authors:  Chelsea Schiliro; Bonnie L Firestein
Journal:  Cells       Date:  2021-04-29       Impact factor: 6.600

6.  Inhibition of Glucose-6-Phosphate Dehydrogenase Reverses Cisplatin Resistance in Lung Cancer Cells via the Redox System.

Authors:  Weipeng Hong; Peiheng Cai; Chuncao Xu; Di Cao; Weibang Yu; Zhongxiang Zhao; Min Huang; Jing Jin
Journal:  Front Pharmacol       Date:  2018-01-31       Impact factor: 5.810

7.  Proteomic Investigation to Identify Anticancer Targets of Nemopilema nomurai Jellyfish Venom in Human Hepatocarcinoma HepG2 Cells.

Authors:  Indu Choudhary; Hyunkyoung Lee; Min Jung Pyo; Yunwi Heo; Jinho Chae; Seung Shic Yum; Changkeun Kang; Euikyung Kim
Journal:  Toxins (Basel)       Date:  2018-05-10       Impact factor: 4.546

8.  Correcting glucose-6-phosphate dehydrogenase deficiency with a small-molecule activator.

Authors:  Sunhee Hwang; Karen Mruk; Simin Rahighi; Andrew G Raub; Che-Hong Chen; Lisa E Dorn; Naoki Horikoshi; Soichi Wakatsuki; James K Chen; Daria Mochly-Rosen
Journal:  Nat Commun       Date:  2018-10-02       Impact factor: 14.919

9.  Activation of pro-survival metabolic networks by 1,25(OH)2D3 does not hamper the sensitivity of breast cancer cells to chemotherapeutics.

Authors:  Mohamed A Abu El Maaty; Yasamin Dabiri; Fadi Almouhanna; Biljana Blagojevic; Jannick Theobald; Michael Büttner; Stefan Wölfl
Journal:  Cancer Metab       Date:  2018-08-30

10.  ROCK Inhibitor Y-27632 Promotes Human Retinal Pigment Epithelium Survival by Altering Cellular Biomechanical Properties.

Authors:  Y Ni; Y Qin; Z Fang; Z Zhang
Journal:  Curr Mol Med       Date:  2017       Impact factor: 2.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.